Lobbying client
MILANAPHARM
Specialty pharmaceutical company with a proprietary drug delivery platform
Filings
32
Filed by
1
Reported in-house
—
Reported by firms
—
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2019 to 2026
Filings
32 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Termination (No Activity) 3rd Quarter 2026
|
FORBES-TATE | — reported |
|
2nd Quarter - Report (No Activity) 2nd Quarter 2026
|
FORBES-TATE | — reported |
|
1st Quarter - Report (No Activity) 1st Quarter 2026
|
FORBES-TATE | — reported |
|
4th Quarter - Report (No Activity) 4th Quarter 2025
|
FORBES-TATE | — reported |
|
3rd Quarter - Report (No Activity) 3rd Quarter 2025
|
FORBES-TATE | — reported |
|
2nd Quarter - Report (No Activity) 2nd Quarter 2025
|
FORBES-TATE | — reported |
|
1st Quarter - Report (No Activity) 1st Quarter 2025
|
FORBES-TATE | — reported |
|
4th Quarter - Report (No Activity) 4th Quarter 2024
|
FORBES-TATE | — reported |
|
3rd Quarter - Report (No Activity) 3rd Quarter 2024
|
FORBES-TATE | — reported |
|
2nd Quarter - Report (No Activity) 2nd Quarter 2024
|
FORBES-TATE | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| FORBES-TATE | 31 | — |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 14 |
| Budget/Appropriations | BUD | 2 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.